BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

766 related articles for article (PubMed ID: 17986219)

  • 1. Sensitive biochemical aggregate detection reveals aggregation onset before symptom development in cellular and murine models of Huntington's disease.
    Weiss A; Klein C; Woodman B; Sathasivam K; Bibel M; Régulier E; Bates GP; Paganetti P
    J Neurochem; 2008 Feb; 104(3):846-58. PubMed ID: 17986219
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of neuron-specific huntingtin aggregates in human huntingtin knock-in mice.
    Sawada H; Ishiguro H; Nishii K; Yamada K; Tsuchida K; Takahashi H; Goto J; Kanazawa I; Nagatsu T
    Neurosci Res; 2007 Apr; 57(4):559-73. PubMed ID: 17335925
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The selective vulnerability of nerve cells in Huntington's disease.
    Sieradzan KA; Mann DM
    Neuropathol Appl Neurobiol; 2001 Feb; 27(1):1-21. PubMed ID: 11298997
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transgenic mice expressing mutated full-length HD cDNA: a paradigm for locomotor changes and selective neuronal loss in Huntington's disease.
    Reddy PH; Charles V; Williams M; Miller G; Whetsell WO; Tagle DA
    Philos Trans R Soc Lond B Biol Sci; 1999 Jun; 354(1386):1035-45. PubMed ID: 10434303
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amyloid formation by mutant huntingtin: threshold, progressivity and recruitment of normal polyglutamine proteins.
    Huang CC; Faber PW; Persichetti F; Mittal V; Vonsattel JP; MacDonald ME; Gusella JF
    Somat Cell Mol Genet; 1998 Jul; 24(4):217-33. PubMed ID: 10410676
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Olesoxime suppresses calpain activation and mutant huntingtin fragmentation in the BACHD rat.
    Clemens LE; Weber JJ; Wlodkowski TT; Yu-Taeger L; Michaud M; Calaminus C; Eckert SH; Gaca J; Weiss A; Magg JC; Jansson EK; Eckert GP; Pichler BJ; Bordet T; Pruss RM; Riess O; Nguyen HP
    Brain; 2015 Dec; 138(Pt 12):3632-53. PubMed ID: 26490331
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evidence for both the nucleus and cytoplasm as subcellular sites of pathogenesis in Huntington's disease in cell culture and in transgenic mice expressing mutant huntingtin.
    Hackam AS; Hodgson JG; Singaraja R; Zhang T; Gan L; Gutekunst CA; Hersch SM; Hayden MR
    Philos Trans R Soc Lond B Biol Sci; 1999 Jun; 354(1386):1047-55. PubMed ID: 10434304
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutant huntingtin causes context-dependent neurodegeneration in mice with Huntington's disease.
    Yu ZX; Li SH; Evans J; Pillarisetti A; Li H; Li XJ
    J Neurosci; 2003 Mar; 23(6):2193-202. PubMed ID: 12657678
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A critical window of CAG repeat-length correlates with phenotype severity in the R6/2 mouse model of Huntington's disease.
    Cummings DM; Alaghband Y; Hickey MA; Joshi PR; Hong SC; Zhu C; Ando TK; André VM; Cepeda C; Watson JB; Levine MS
    J Neurophysiol; 2012 Jan; 107(2):677-91. PubMed ID: 22072510
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutant huntingtin and glycogen synthase kinase 3-beta accumulate in neuronal lipid rafts of a presymptomatic knock-in mouse model of Huntington's disease.
    Valencia A; Reeves PB; Sapp E; Li X; Alexander J; Kegel KB; Chase K; Aronin N; DiFiglia M
    J Neurosci Res; 2010 Jan; 88(1):179-90. PubMed ID: 19642201
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early motor dysfunction and striosomal distribution of huntingtin microaggregates in Huntington's disease knock-in mice.
    Menalled LB; Sison JD; Wu Y; Olivieri M; Li XJ; Li H; Zeitlin S; Chesselet MF
    J Neurosci; 2002 Sep; 22(18):8266-76. PubMed ID: 12223581
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 14-3-3zeta is indispensable for aggregate formation of polyglutamine-expanded huntingtin protein.
    Omi K; Hachiya NS; Tanaka M; Tokunaga K; Kaneko K
    Neurosci Lett; 2008 Jan; 431(1):45-50. PubMed ID: 18078716
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes in cortical and striatal neurons predict behavioral and electrophysiological abnormalities in a transgenic murine model of Huntington's disease.
    Laforet GA; Sapp E; Chase K; McIntyre C; Boyce FM; Campbell M; Cadigan BA; Warzecki L; Tagle DA; Reddy PH; Cepeda C; Calvert CR; Jokel ES; Klapstein GJ; Ariano MA; Levine MS; DiFiglia M; Aronin N
    J Neurosci; 2001 Dec; 21(23):9112-23. PubMed ID: 11717344
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BH3-only proteins Bid and Bim(EL) are differentially involved in neuronal dysfunction in mouse models of Huntington's disease.
    García-Martínez JM; Pérez-Navarro E; Xifró X; Canals JM; Díaz-Hernández M; Trioulier Y; Brouillet E; Lucas JJ; Alberch J
    J Neurosci Res; 2007 Sep; 85(12):2756-69. PubMed ID: 17387706
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TR-FRET-based duplex immunoassay reveals an inverse correlation of soluble and aggregated mutant huntingtin in huntington's disease.
    Baldo B; Paganetti P; Grueninger S; Marcellin D; Kaltenbach LS; Lo DC; Semmelroth M; Zivanovic A; Abramowski D; Smith D; Lotz GP; Bates GP; Weiss A
    Chem Biol; 2012 Feb; 19(2):264-75. PubMed ID: 22365609
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Huntingtin aggregate-associated axonal degeneration is an early pathological event in Huntington's disease mice.
    Li H; Li SH; Yu ZX; Shelbourne P; Li XJ
    J Neurosci; 2001 Nov; 21(21):8473-81. PubMed ID: 11606636
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tissue-specific proteolysis of Huntingtin (htt) in human brain: evidence of enhanced levels of N- and C-terminal htt fragments in Huntington's disease striatum.
    Mende-Mueller LM; Toneff T; Hwang SR; Chesselet MF; Hook VY
    J Neurosci; 2001 Mar; 21(6):1830-7. PubMed ID: 11245667
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Uninterrupted CAG repeat drives striatum-selective transcriptionopathy and nuclear pathogenesis in human Huntingtin BAC mice.
    Gu X; Richman J; Langfelder P; Wang N; Zhang S; Bañez-Coronel M; Wang HB; Yang L; Ramanathan L; Deng L; Park CS; Choi CR; Cantle JP; Gao F; Gray M; Coppola G; Bates GP; Ranum LPW; Horvath S; Colwell CS; Yang XW
    Neuron; 2022 Apr; 110(7):1173-1192.e7. PubMed ID: 35114102
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A CAG repeat threshold for therapeutics targeting somatic instability in Huntington's disease.
    Aldous SG; Smith EJ; Landles C; Osborne GF; Cañibano-Pico M; Nita IM; Phillips J; Zhang Y; Jin B; Hirst MB; Benn CL; Bond BC; Edelmann W; Greene JR; Bates GP
    Brain; 2024 May; 147(5):1784-1798. PubMed ID: 38387080
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neurodegeneration. Huntington's research points to possible new therapies.
    Marx J
    Science; 2005 Oct; 310(5745):43-5. PubMed ID: 16210515
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 39.